CurrentHealth NetPolicy CP PHAR.126

Ibrutinib (Imbruvica) — Clinical Policy

Policy governing medical necessity and prior authorization criteria for ibrutinib (Imbruvica) across Commercial, HIM, and Medicaid lines of business for oncology indications and select NCCN‑recommended off‑label uses.

Policy Summary

PayerHealth Net

PolicyIbrutinib (Imbruvica) — Clinical Policy

Policy CodePolicy CP PHAR.126

Change TypeNo material changes

Effective DateOct 1, 2015

Next Review Date

Key ActionSubmit prior authorization with supporting clinical documentation (office notes, labs) showing the member meets criteria and prior therapies as required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3FDA indications

6/12 moApproval duration

≥1 yrPediatric cGVHD lower age

420 mgCommon max dose

Coverage Criteria

Initial Therapy — CLL/SLL — ALL criteria for coverage

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial CLL/SLL criteria: 1) Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); 2) Prescribed by or in consultation with an oncologist or hematologist; 3) Age ≥ 18 years; 4) Prescribed as a single agent or in combination with Venclexta (venetoclax); 5) Member must use generic ibrutinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 6) Dose and formulation limits met: for tablets, 420 mg per day (prescribed quantity does not exceed 1 tablet/day); for capsules, dose < 420 mg per day (prescribed quantity does not exceed 3 capsules/day); for oral suspension, dose does not exceed 420 mg (6 mL) per day; 7) Prescribed regimen is FDA‑approved or recommended by NCCN, or the requested dose/regimen is supported by practice guidelines or peer‑reviewed literature with supporting evidence submitted by the prescriber.

Initial Therapy — Waldenström macroglobulinemia — ALL criteria for coverage

Covered when ALL of the following are met:

Initial WM criteria: 1) Diagnosis of Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma (including symptomatic Bing‑Neel syndrome); 2) Prescribed by or in consultation with an oncologist or hematologist; 3) Age ≥ 18 years; 4) Prescribed as a single agent or in combination with rituximab; 5) Member must use generic ibrutinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 6) Dose and formulation limits met: tablets 420 mg/day (≤1 tablet/day); capsules <420 mg/day (≤3 capsules/day); oral suspension ≤420 mg (6 mL)/day; 7) Prescribed regimen is FDA‑approved or recommended by NCCN, or dose/regimen is supported by practice guidelines or peer‑reviewed literature with submitted evidence.

Initial Therapy — chronic Graft‑Versus‑Host Disease — ALL criteria for coverage

Covered when ALL of the following are met:

Initial cGVHD criteria: 1) Diagnosis of chronic graft‑versus‑host disease (cGVHD); 2) Prescribed by or in consultation with an oncologist, hematologist, or bone marrow/stem cell transplant specialist; 3) History of bone marrow/stem cell transplant; 4) Member must use generic ibrutinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 5) Failure of a systemic corticosteroid and failure of a systemic immunosuppressant (each given at up to maximally indicated doses) unless contraindicated or clinically significant adverse effects are experienced; 6) Dose and formulation limits met, including pediatric dosing where applicable (for age 1 to <12 years: 240 mg/m2 per day), and Imbruvica is not prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil); 7) Prescribed regimen is FDA‑approved or recommended by NCCN or supported by practice guidelines/peer‑reviewed literature with submitted evidence.

Initial Therapy — NCCN compendium indications (off‑label) — ALL criteria for covered off‑label uses

Covered when ALL of the following are met for NCCN compendium off‑label indications:

NCCN compendium criteria: 1) Diagnosis corresponds to a listed NCCN compendium indication (examples include primary CNS lymphoma, brain metastases in lymphoma, mantle cell lymphoma [MCL], hairy cell leukemia [HCL], post‑transplant lymphoproliferative disorder [PTLD], various B‑cell lymphoma subtypes such as DLBCL or marginal zone lymphoma subtypes); 2) Age > 18 years unless specific pediatric dosing is noted; 3) Prescribed by or in consultation with an oncologist or hematologist; 4) Member must use generic ibrutinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 5) For oral suspension requests at 420 mg/day, documentation supports inability to swallow capsules/tablets when applicable; 6) Dose and formulation limits met (tablets 420 mg/day ≤1 tablet/day; capsules <420 mg/day ≤3 capsules/day; oral suspension ≤420 mg [6 mL]/day); 7) Prescribed regimen is FDA‑approved or recommended by NCCN, or dose/regimen is supported by practice guidelines or peer‑reviewed literature with submitted evidence. Additional indication‑specific subcriteria apply (e.g., MCL in combination with rituximab as pretreatment to limit aggressive induction, HCL for progressive disease after prior therapy, prior lines of therapy where specified).

Coverage overview / indication-linked criteria — policy guidance linking NCCN and labeling across indications

Coverage is guided by NCCN recommendations and product labeling; specific criteria vary by indication and have been updated over time (see revision history).

Dosing and formulation: Standard adult dosing commonly 420 mg PO once daily for many indications; pediatric dosing for cGVHD specified (age ≥12 years: 420 mg PO QD; age 1 to <12 years: 240 mg/m2 PO QD up to a maximum of 420 mg/day).420 mg/day

See product availability for formulations (capsules, tablets, oral suspension).

Therapeutic trial for cGVHD: Prior trial and failure of both a systemic corticosteroid and a systemic immunosuppressant at up to maximally indicated doses is required for cGVHD per NCCN and policy history.

Policy history documents alignment with Rezurock approach

Combination therapy updates: For certain indications the policy requires combination regimens per recent NCCN updates (examples: addition of venetoclax for CLL/SLL; for histologic transformation of CLL/SLL to DLBCL require combination with PD‑1 inhibitors such as nivolumab or pembrolizumab).

Refer to full policy revision history for exact indication‑specific combination requirements

Initial Therapy Requirements

Initial therapy requirements — specialist prescribing, age limits, generic alternatives, indication-specific requirements

Initial authorization requirements vary by indication but commonly require ALL of the following:

Common initial requirements: 1) Prescribed by or in consultation with an appropriate specialist (oncologist or hematologist; for cGVHD a bone marrow/stem cell transplant specialist may be required); 2) Age criteria per indication (typically ≥18 years for oncology indications; pediatric dosing exceptions for cGVHD); 3) Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 4) Dose and formulation limits met (capsules, tablets, oral suspension up to 420 mg/day; pediatric dosing as specified); 5) For off‑label/NCCN compendium uses, regimen must be FDA‑approved for the indication or recommended by NCCN or supported by practice guidelines/peer‑reviewed literature with submitted supporting evidence; 6) Documentation for oral suspension requests when 420 mg/day supports inability to swallow capsules/tablets when applicable.

Specialist prescribing and generic redirection language emphasized in policy history.

Initial therapy rules — initial therapy and trial requirements (step rules)

Initial therapy and trial requirements (step rules):

cGVHD initial requirement: For chronic GVHD, trial and failure of both a systemic corticosteroid and a systemic immunosuppressant (each given at up to maximally indicated doses) is required prior to approval of ibrutinib unless contraindicated or clinically significant adverse effects are experienced.

Requirement aligned with NCCN and Imbruvica pivotal trial per policy history.

Indication-specific step updates: Policy includes step or combination therapy requirements per NCCN for selected indications (for example, combination with venetoclax for CLL/SLL or rituximab in select MCL uses as detailed in the policy revision history).

Refer to revision history for dates of specific updates.

Continuation / Continued Therapy

Continuation Therapy — ALL criteria required for ongoing coverage

Covered when ALL of the following are met for continuation:

Continuation criteria: 1) Documentation supports that the member is currently receiving Imbruvica for a covered oncology‑related indication and has received therapy for at least 30 days; 2) Member is responding positively to therapy; 3) Member must use generic ibrutinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4) For cGVHD, Imbruvica is not prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil); 5) Dose increases must meet the specified dose/formulation limits or be supported by practice guidelines or peer‑reviewed literature with submitted evidence for off‑label use.

Continued therapy — criteria for continued coverage (operational)

Operational criteria for continued coverage and approvals:

Operational continuation nodes: 1) Provider must submit documentation (office notes, labs, imaging, or other clinical information) demonstrating member has met continuation criteria including at least 30 days of therapy and clinical response; 2) Oral suspension continuation at 420 mg/day requires documentation of inability to swallow capsules/tablets when applicable; 3) Approval durations follow line‑of‑business limits (Medicaid/HIM typically 6 months per some history entries and commercial approvals revised to 12 months or duration of request, whichever is less); 4) Requests for dose escalation must conform to capsule/tablet/suspension limits or be supported by submitted literature/guidelines.

Commercial approval duration limited to 12 months or duration of request, whichever is less.

Continuation therapy duration — approval duration and continuation considerations

Continuation approval duration and considerations:

Continuation approval duration: Commercial approvals are revised to a maximum of 12 months or the duration of the request, whichever is less; Medicaid and HIM approval durations are noted as 6 months in portions of the policy history and may differ by line of business — verify per benefit plan and prior authorization rules.

Refer to prior authorization module and plan‑specific rules for exact duration.

Continuation considerations: Continued coverage requires ongoing clinical benefit; documentation must support continued response and adherence to dosing/formulation limits. For cGVHD, concurrent use with Jakafi or Rezurock is not permitted for continuation requests.

Step Therapy and Required Trials

Required prior therapy (cGVHD)	Notes / details
Failure of a systemic corticosteroid at up to maximally indicated doses
Policy text specifies 'failure of a systemic corticosteroid (see Appendix B) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced.'
Failure of a systemic immunosuppressant at up to maximally indicated doses
Policy text specifies 'failure of a systemic immunosuppressant (see Appendix B) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced.'
History of bone marrow/stem cell transplant
Member must have a history of bone marrow/stem cell transplant as part of cGVHD diagnosis criteria.
Specialist involvement: prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist
Policy requires specialist prescribing or consultation for cGVHD requests.
Generic ibrutinib used if available unless contraindicated
Policy requires use of generic ibrutinib if available unless contraindicated or clinically significant adverse effects occur.
Contraindicated concurrent therapies
Imbruvica is not to be prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil) for cGVHD per policy guidance.

Indication / context	Step or combination requirement (per NCCN / policy history)	Effective revision note (policy history)
CLL/SLL (initial therapy)
Ibrutinib may be prescribed as single agent or in combination with venetoclax (Venclexta) — combination requirement added per NCCN in 1Q 2025 for certain CLL/SLL regimens.
1Q 2025 annual review: per NCCN guidelines added combo use with Venclexta for CLL/SLL (P&T Approval Date = 02.25).
Histologic transformation of CLL/SLL to DLBCL
Policy now requires combination therapy with PD-1 inhibitors (e.g., nivolumab/Opdivo or pembrolizumab/Keytruda) for histologic transformation to DLBCL as of 1Q 2025 updates.
1Q 2025 annual review: for histologic transformation of CLL/SLL to DLBCL added requirement for combo use with Opdivo or Keytruda.
Mantle cell lymphoma (MCL) and other B-cell malignancies
Policy history documents prior additions clarifying combination with rituximab for MCL and other NCCN-directed combination language in earlier reviews (1Q 2021 and subsequent updates).
1Q 2021 annual review: for MCL, NCCN-directed language inserted to clarify combination therapy with rituximab; subsequent reviews updated nomenclature and indications through 2024.

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization and Approval Duration

Prior authorization is required for Imbruvica. Approval durations vary by line of business: for Medicaid/HIM the approval duration is 6 months; for Commercial the approval duration is limited to 12 months or the duration of the request, whichever is less.

Medicaid/HIM: 6 months
Commercial: 12 months or duration of request, whichever is less

Denial Risk

Non‑Covered Indications Risk

Requests for indications that are not FDA‑approved and not addressed in this policy may be denied unless the provider supplies sufficient documentation supporting safety and efficacy per applicable off‑label use policies (CP CPA.09 for commercial, HIM.PA.154 for Marketplace, CPPMN.53 for Medicaid) or other evidence of coverage documents.

Non‑FDA approved indications require supporting documentation per off‑label policies
Lack of adequate evidence may result in denial

Documentation Required

Required Documentation and Supporting References

Provider must submit documentation (e.g., office chart notes, laboratory results, or other clinical information) that supports the member has met all approval criteria. References and prescribing information that may support the request should be included (for example: Imbruvica prescribing information and relevant NCCN guidelines/compendia).

Submit chart notes, labs, and other clinical information
Include relevant references such as Imbruvica Prescribing Information and NCCN guidelines/Drug & Biologics Compendium

Step Therapy

Therapeutic Trial Requirements for cGVHD

For chronic graft‑versus‑host disease (cGVHD) requests, the member must have failed both a systemic corticosteroid and a systemic immunosuppressant (each at up to maximally indicated doses unless contraindicated or significant adverse effects occur) prior to approval. Additional criteria for cGVHD (age, transplant history, prescribing specialist, use of generic ibrutinib if available, and concurrent therapy exclusions) must also be met and documented.

Therapeutic trial requirement for cGVHD: failure of a systemic corticosteroid AND a systemic immunosuppressant
Document age, history of bone marrow/stem cell transplant, specialist consultation, and use of generic ibrutinib if available
Imbruvica must not be used concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil) for cGVHD

Quantity and Dosing Limits

Ibrutinib — dose/formulation limits

Capsules — strengths and limitAvailable strengths: 70 mg, 140 mg; capsules limited to doses < 420 mg/day (max 3 capsules/day)

Tablets — strengths and limitAvailable tablet strengths include 140 mg, 280 mg, 420 mg; tablet dosing capped at 420 mg/day (max 1 tablet/day)

Oral suspension — concentration and limitOral suspension: 70 mg/mL; limited to 420 mg/day (6 mL)

Overall per-formulation capPer-formulation limits permit up to 420 mg/day across capsules, tablets, or suspension

Ibrutinib — numeric maximum daily dose summary

Numeric maximum daily dose (summary)420 mg/day

Maximum expressed as capsules/tablet/suspensionEquivalent to 3 capsules/day (capsule regimen), 1 tablet/day (tablet regimen), or 6 mL oral suspension/day

Documented maximum across indications420 mg/day cited as maximum for CLL/SLL, WM, and many adult indications

Coding and Dose References

Maximum daily dose — dosing quick reference

Quick reference — adult maximum420 mg PO once daily (maximum 420 mg/day)

Capsule quick limitCapsules: dose must be < 420 mg/day; up to 3 capsules/day

Tablet quick limitTablets: dose = 420 mg/day; up to 1 tablet/day

Oral suspension quick limitOral suspension: up to 420 mg (6 mL) per day

Pediatric cGVHD dose for age 1 to <12 years — pediatric dosing reference

Pediatric cGVHD (age 1 to <12 yrs) — dose240 mg per m2 per day (oral suspension) up to a maximum of 420 mg/day

Pediatric older childrenAge ≥12 years: 420 mg PO once daily (same as adult dosing)

Formulation for pediatric dosingOral suspension specified for younger pediatric patients who cannot swallow capsules/tablets

Maximum daily dose — alternate numeric dose summary

Alternate numeric maximum doseMaximum dose commonly referenced: 420 mg/day

Equivalent formulations420 mg/day corresponds to 3 capsules, 1 tablet, or 6 mL oral suspension

Policy noteDose increases must meet formulation limits or be supported by guidelines/peer‑reviewed literature for off‑label uses

Definitions and Acronyms

BTK definition

BTKBTK: Bruton's tyrosine kinase

Class descriptionBTK is the molecular target class for ibrutinib (a BTK inhibitor)

RelevanceBTK inhibition is the therapeutic mechanism for multiple B‑cell malignancies and cGVHD

cGVHD definition

cGVHDcGVHD: chronic graft‑versus‑host disease

Clinical contextcGVHD occurs after bone marrow/stem cell transplant and is an indicated use for ibrutinib in patients ≥1 year with prior therapy failure

Therapy cautionIbrutinib should not be prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil) for cGVHD per policy

CLL definition

CLLCLL: chronic lymphocytic leukemia

Indication noteIbrutinib is covered for CLL/SLL in adults when criteria are met (specialist prescribing, dosing limits, generic use if available)

Related termsSLL (small lymphocytic lymphoma) is included with CLL in coverage criteria

cGVHD — therapy examples and required trials summary

Required therapeutic trials for cGVHDFailure of a systemic corticosteroid and a systemic immunosuppressant at up to maximally indicated doses is required prior to approval

Examples of systemic immunosuppressantsAppendix B lists systemic immunosuppressants and examples of other systemic therapies used for B‑cell malignancies and transplant‑related indications

Policy history relevancePolicy revisions across 2021 clarified cGVHD trial requirements and concurrency restrictions with Rezurock and Jakafi

Revision History

2025-02-25P&T approvalLatest

1Q 2025 annual review: per NCCN guidelines added combination use with venetoclax (Venclexta) for CLL/SLL; for histologic transformation of CLL/SLL to DLBCL added requirement for combination use with nivolumab or pembrolizumab (Opdivo or Keytruda); nomenclature updates for MALT/MZL and relapsed/refractory requirements; references reviewed and updated.

2024-12-02annual review

References reviewed and updated; terminology changes aligning MALT lymphoma to Extranodal MZL (noncutaneous) and added relapsed/refractory/progressive disease requirement for Nodal and Extranodal MZL.

2023-01-01annual review

1Q 2023 annual review: removed certain combination recommendations (Rituxan, Gazyva, bendamustine) for CLL/SLL; added Bing‑Neel syndrome as a WM subtype treatable with ibrutinib; removed follicular lymphoma as an NCCN compendial off‑label indication.

2022-11-17P&T approval / annual review

1Q 2022 annual review: removed indication for histologic (Richter's) transformation per NCCN (category 2B); added lymphoplasmacytic lymphoma to WM criteria; clarified that cGVHD requires trial of both a systemic corticosteroid and a systemic immunosuppressant.

2021-11-21P&T approval / update

Updated Appendix B and added language that Imbruvica, Rezurock, and Jakafi are not to be used concurrently for cGVHD; clarified MCL combination therapy with rituximab and other indication-specific clarifications from 1Q 2021 review.

2020-11-09P&T approval / annual review

1Q 2021 annual review (documented with 11.09.20 reference): added oral oncology generic redirection language; for MCL inserted NCCN‑directed combination language with rituximab; added histologic transformation combination therapy per NCCN and broadened MZL subtype delineation and therapy trials; cGVHD trial requirement edited to require corticosteroid plus immunosuppressant.